1. Home
  2. IMSR vs ESPR Comparison

IMSR vs ESPR Comparison

Compare IMSR & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMSR

Terrestrial Energy Inc.

N/A

Current Price

$7.83

Market Cap

825.8M

Sector

N/A

ML Signal

N/A

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$1.90

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMSR
ESPR
Founded
2013
2008
Country
United States
United States
Employees
74
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
825.8M
731.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
IMSR
ESPR
Price
$7.83
$1.90
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.75
AVG Volume (30 Days)
2.0M
7.4M
Earning Date
05-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$5.33
$0.73
52 Week High
$16.38
$4.18

Technical Indicators

Market Signals
Indicator
IMSR
ESPR
Relative Strength Index (RSI) 60.03 31.41
Support Level $7.52 $1.34
Resistance Level $11.04 $2.08
Average True Range (ATR) 0.67 0.16
MACD 0.17 -0.01
Stochastic Oscillator 64.00 11.89

Price Performance

Historical Comparison
IMSR
ESPR

About IMSR Terrestrial Energy Inc.

Terrestrial Energy Inc is a technology company engaged in the development and commercialization of nuclear power plants. The company is focused on its proprietary Integral Molten Salt Reactor (IMSR) technology, a Generation IV reactor design intended to produce reliable, emission-free energy in the form of electricity and high-temperature heat for industrial applications. Its activities mainly involve advancing the design, licensing, and deployment of IMSR plants for commercial energy generation.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: